Company news

Recce Pharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Positive Oral Data on New RECCE 435 Against H. pylori

August 4, 2020

US Researchers to Test RECCE in Expanded SARS-CoV-2 Program

July 16, 2020

RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program

July 8, 2020

Response to ASX Price and Volume Query

May 27, 2020

Positive Data on RECCE 327 Against Neisseria gonorrhoeae

May 4, 2020

Further Positive Data on RECCE 327 Against MRSA Superbug

April 23, 2020

Positive Data on RECCE 327 Against Influenza A

April 20, 2020

Recce Signs Phase I Human Clinical Trial Agreement

April 8, 2020

First-in-Human Clinical Trial Progress Update

March 16, 2020

Half Yearly Report and Accounts

February 27, 2020

Positive Efficacy Data in Kidney/UTI infections animal model

February 13, 2020

Positive Data from RECCE 327 Antibiotic Safety Studies

February 9, 2020

Appendix 4C and Commentary

January 31, 2020

Positive Data for RECCE 327 in MRSA Burns Wound Infection

November 26, 2019

Recce Completes Raising of $6.76 million

October 9, 2019

Key Family 2 Patent Granted in Japan for RECCE Antibiotics

September 20, 2019

Funding Update

September 11, 2019

Appendix 4E - Preliminary Final Report

August 30, 2019

FDA Positive Response for Recce Scaled Manufacture & Quality

August 26, 2019

Response to ASX Appendix 4C Query

August 16, 2019

Key Family 2 Patent Granted in Europe for RECCE Antibiotics

August 8, 2019

Opening R&D Address at World Antibiotic Resistance Congress

July 31, 2019

Appendix 4C and commentary

July 30, 2019

Appointment of Independent Chair and Additional Director

July 9, 2019

USA Patent Granted for Recces Antibiotics

March 13, 2019

Recce Successfully Raises $1.8 million via Placement

February 7, 2019

Change of Registry Address: Automic P/L - Sydney Office

September 28, 2018

Key Australian Patent for Recces Broad-Spectrum Antibiotics

July 31, 2018

Update on Progress of Broad Spectrum Antibiotic RECCE 327

July 18, 2018

Update on meeting with US FDA

June 5, 2018

Additional AU$861,590 R&D Tax Incentive Rebate Received

April 22, 2018

Recce Half Yearly Report and Appendix 4D

February 28, 2018

Data Submission & Further Communication Request with US FDA

February 14, 2018

AusIndustry Awards Recce Financial Support

January 14, 2018

US FDA Grants Qualified Infectious Disease Product Designati

November 15, 2017

Appendix 4C - quarterly

October 31, 2017

Recce Launches Share Purchase Plan

September 27, 2017

Response to ASX Price Query

September 18, 2017

Recce Confirms Pre-IND Data Submission to US FDA

September 6, 2017

Appendix 4E and Financial Report

August 31, 2017

Recce Confirms Delivery by Intravenous Drip

July 30, 2017

Recce achieves milestone with volume production

July 19, 2017

Recce constructs automated manufacturing facility to support

June 22, 2017

Recce secures up to A$6.05 million investment agreement with

June 16, 2017

Recce moves closer to clinical study application

May 19, 2017

Operational Update

April 9, 2017

Data from large animal study shows RECCE 327 well tolerated

March 26, 2017

Appendix 4D and Interim Financial Statements

February 28, 2017

Microscopy Images of its Synthetic Antibiotic in Action Dest

February 23, 2017

Recce to suspend anti-cancer program

February 22, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 45 decks. Every deck is listed under its year.